Shares of Delcath Systems Inc (NASDAQ:DCTH) rose sharply in pre-market trading after the company announced preliminary third quarter 2025 financial results.

The company's Phase 2 CHOPIN study achieved primary endpoint, with PHP plus immunotherapy extending median PFS to 12.8 months versus 8.3 months.

Delcath Systems shares jumped 14.2% to $13.66 in the pre-market trading session.

Here are some other stocks moving in pre-market trading.

Gainers

• Beyond Meat Inc (NASDAQ:BYND) gained 76.6% to $1.14 in pre-market trading after surging 24% on Friday.
• FGI Industries Ltd (NASDAQ:FGI) surged 64.1% to $7.81 in pre-market trading.
• Celcuity Inc (NASDAQ:CELC) surged 44.3% to $75.00 in pre-market trading after the company announced Phase 3 VIKTORIA-1 data.
• Vivakor inc (NASDAQ:VIVK) rose 41.3% to $0.29 in pre-market trading. Vivakor, last week, announced approximately $5.0 million registered direct offering priced at-the-market under Nasdaq rules.
• Rani Therapeutics Holdings Inc (NASDAQ:RANI) surged 32.5% to $2.18 in pre-market trading. Rani Therapeutics Holdings shares jumped 248% on Friday after the company announced a Collaboration and License Agreement with Chugai Pharmaceutical for the development and commercialization of an oral product. The company announced an oversubscribed $60.3 million private placement.
• Focus Universal Inc (NASDAQ:FCUV) rose 23.5% to $4.49 in pre-market trading after dipping more than 10% on Friday.
• NuCana PLC (NASDAQ:NCNA) gained 22.1% to $6.19 in pre-market trading. NuCana highlighted synergy between NUC-7738 and PD-1 inhibitors in RCC Organoids, supporting expansion of NuTide:701 clinical study.
• Digi Power X Inc (NASDAQ:DGXX) gained 17.4% to $4.51 in pre-market trading after adding around 8% on Friday.
• Rapt Therapeutics Inc (NASDAQ:RAPT) rose 16.3% to $34.17 in pre-market trading. RAPT Therapeutics will release Phase 2 RPT904 data addressing immune modulation in chronic spontaneous urticaria during October 20 webcast.

Losers

• MingZhu Logistics Holdings Ltd (NASDAQ:YGMZ) tumbled 79.6% to $0.19 in pre-market trading after declining 6% on Friday.
• FlexShopper Inc (NASDAQ:FPAY) declined 37.1% to $0.20 in pre-market trading after the company received a delisting notification from the Nasdaq.
• Tianci International Inc (NASDAQ:CIIT) fell 30.5% to $0.61 in pre-market trading after gaining more than 52% on Friday.
• Growhub Ltd (NASDAQ:TGHL) shares dipped 27.4% to $1.03 in pre-market trading after gaining 6% on Friday.
• FBS Global Ltd (NASDAQ:FBGL) fell 25.2% to $0.43 in pre-market trading. FBS Global filed for offering minimum of 20 million ordinary shares, maximum of 40 million ordinary shares at offering price of $0.25 per share.
• Concord Medical Services Hldgs Ltd (NYSE:CCM) fell 24.4% to $4.15 in pre-market trading after dipping 6% on Friday.
• XORTX Therapeutics Inc (NASDAQ:XRTX) dipped 22.3% to $0.85 in pre-market trading. XORTX Therapeutics shares jumped 29% on Friday after the company announced it will acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystem.
• Olema Pharmaceuticals Inc (NASDAQ:OLMA) fell 18.3% to $7.64 in pre-market trading after the company announced new data from the Phase 1b/2 trial of palazestrant plus ribociclib in ER+/HER2- metastatic breast cancer at ESMO 2025.
• Addex Therapeutics Ltd – ADR (NASDAQ:ADXN) dipped 15.6% to $9.23 in pre-market trading after gaining 28% on Friday.
• Exelixis Inc (NASDAQ:EXEL) fell 8.3% to $36.00 after the company announced detailed results from Phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer presented at ESMO 2025 and published in The Lancet.

Now Read This:

• ‘No Need To Sell’ Martin Marietta Materials, Cramer Says: ‘It’s Just A Great Long-Term Hold’

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.